|
The Week Ahead: Treating HCV — Is the Price Right?
MedPage Today Pulmonology — An FDA advisory board will weigh the risks and benefits of a sleep apnea “pacemaker” device. Rheumatology — Can rituximab help in Sjogren’s syndrome? Nancy Walsh, rheumatology bureau chief, analyzes the data to answer that question. |
Medscape |
FDA Sends Valentine to CLL Patients
Medscape There is the FCR [fludarabine, cyclophosphamide, rituximab] front-line group, and the BR [bendamustine, rituximab] front-line group, but whichever one you use, there isn’t a good salvage regimen. Alemtuzumab had been approved but is now off the market. |
|
Actemra Aids in Adult Still’s
MedPage Today Various biologics also have been tried, including the anti-TNF agents, anakinra, rituximab, and abatacept, but with limited benefit and potentially serious adverse events. Because there have been case reports and small short-term series suggesting some … |
Rheuminations: Comparative Studies Needed for RA BiologicsMedPage TodayIn one study, SWITCH-RA, patients given rituximab rather than a second TNF inhibitor had significantly better results on disease activity scores after 6 months. However, in a study …
|
Rheuminations: Arthritis Tx the EULAR Way
MedPage Today The American College of Rheumatology (ACR) guidelines state that “if after 3 months of methotrexate monotherapy or DMARD combination therapy … the panel recommends adding or switching to an anti-TNF biologic, abatacept, or rituximab [Rituxan].”. |
RA Treatment: When Biologic FailsMedPage TodayThe most commonly used non-TNF agents in RA are rituximab (Rituxan), a B-cell-depleting monoclonal antibody, abatacept (Orencia), a selective T-cell costimulation modulator, and tocilizumab (Actemra), a mon…
|
Young mother was determined to see her boys grow up
Waterloo Record In her notes, Dr. Campbell wrote “it was because of patients like Kim going through this program that Rituximab became a standard addition to chemotherapy programs now for all patients and (it) provides years more freedom from disease.” Kim was always … |
OncLive |
Six Targeted Agents for CLL Command Spotlight at ASH
OncLive Brown also expressed excitement about idelalisib, a first-in-class PI3K-delta inhibitor that—in combination with rituximab— sparked a >70% improvement in OS in patients with high-risk relapsed/refractory CLL; IPI-145, an inhibitor of PI3K-delta and … |
RA: Rituximab Preferred After TNF Inhibitor FailureMedscapePatients with rheumatoid arthritis (RA) who have an inadequate response to a single TNF inhibitor (TNFi) generally do better if they switch to rituximab, rather than to an alternative TNF inhib…
Roach: Devic disease is autoimmune attack on optic nerveAlexandria Town TalkAntibodies show up in her bloodwork. She is about to undergo two treatments, two weeks apart, of rituximab, hopefully killing the antibodies. What little information I have fou…